FDA Extends Review of Tolebrutinib | National MS Society Tolebrutinib — an oral BTK-inhibitor — would mark the first disease-modifying therapy specifically to treat non-relapsing secondary progressive MS The extension is the result of new analyses that were submitted during the review, which the FDA says warrants changes to the new drug application
FDA starts review of Sanofis MS hope tolebrutinib Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator
Tolebrutinib: What is it and is it FDA approved? - Drugs. com Current FDA approval status, regulatory history, and clinical trial results for tolebrutinib, an investigational treatment for non-relapsing secondary progressive multiple sclerosis from the development pipeline at Sanofi
Tolebrutinib for MS | Multiple Sclerosis News Today What is tolebrutinib for MS? Tolebrutinib is an oral therapy being developed by Sanofi to treat both relapsing and progressive forms of multiple sclerosis (MS)
Tolebrutinib - Sanofi Learn more about clinical trial timelines and designs for Sanofi’s investigational brain-penetrant BTK inhibitor for MS treatment
Tolebrutinib - Wikipedia Tolebrutinib Tolebrutinib is an investigational new drug that is being evaluated to treat multiple sclerosis [1] It is a Bruton's tyrosine kinase (BTK) inhibitor [2]